Brainsway Ltd

Brainsway Ltd(BWAY)股票分析

$11.250

-0.187 (-1.66%)收盤時

Loading chart…
最高
11.400
開盤
11.400
成交量加權均價
11.25
成交量
52.46K
市值
100.32M
最低
11.090
成交金額
590.00K
企業價值/稅息折舊攤銷前利潤(TTM)
29.80

Brainsway Ltd is an Israel-based company engaged in the development and marketing of medical devices for the treatment of various neurological and psychopathological disorders. The Company primarily offers Transcranial Magnetic Stimulation (TMS) system, a medical device that enables direct non-invasive activation of deep brain structures. Its TMS system uses magnetic pulses to stimulate neurons and consequently modulates the physiological activity of the brain. TMS system is used in various clinical applications including: major depressive disorders, obsessive-compulsive disorder, smoking addiction and others various psychiatric, neurological, and addiction disorders.

AI 分析 of Brainsway Ltd (BWAY)

持有

While Brainsway Ltd shows promising growth potential with a current price of $11.25 and a forward P/E ratio of 17.92, the RSI of 32.42 indicates it is currently oversold. The recent FDA approval for their Deep TMS technology and a strategic investment of $3 million in Radial Health are positive catalysts. However, the stock has seen a 15.48% decline over the past 20 days, suggesting caution. Given these factors, it may be wise to hold rather than buy at this moment.

估值指標

Brainsway Ltd(BWAY)目前預期本益比為 17.92,5 年平均預期本益比為 42.63。

預期本益比

合理
5 年均值 P/E
42.63
目前P/E
17.92
高估
128.34
低估
-43.07

預期 EV/EBITDA

高估
5 年均值 EV/EBITDA
7.31
目前EV/EBITDA
29.80
高估
24.00
低估
-9.38

預期股價營收比

合理
5 年均值 P/S
3.63
目前P/S
5.40
高估
5.48
低估
1.78

Alphio AI 對 BWAY 的價格情境

情境價格取自當年最後一個月度預測區間。機率為固定的模型權重(25 / 50 / 25),不構成保證。

樂

樂觀

樂觀 · 25%BWAY

$14.03

情境價格

基

基準

基準 · 50%BWAY

$12.23

情境價格

悲

悲觀

悲觀 · 25%BWAY

$10.78

情境價格

持有 BWAY 的大戶

V

Valor Management LLC

+ 持有BWAY

+0.79%

3個月報酬率

M

More Investment House Ltd.

+ 持有BWAY

-15.07%

3個月報酬率

事件時間軸

2026-10-13 (ET)

08:00:00

BrainsWay Expands Medical Policy Coverage to 70 Million in the U.S.

2026-09-08 (ET)

08:00:00

BrainsWay Publishes Results of Deep Brain Stimulation Study

2026-08-12 (ET)

08:00:00

BrainsWay Raises FY26 Financial Guidance to $13M-$14M

08:00:00

BrainsWay Q2 Revenue $12.77M, Raises 2026 Financial Guidance

2026-06-29 (ET)

08:00:00

BrainsWay Presents New Data on Deep TMS for PTSD and Depression

資訊

BWAY 常見問題 —— 由 Alphio AI 解答

Brainsway Ltd is an Israel-based company engaged in the development and marketing of medical devices for the treatment of various neurological and psychopathological disorders. The Company primarily offers Transcranial Magnetic Stimulation (TMS) system, a medical device that enables direct non-invasive activation of deep brain structures. Its TMS system uses magnetic pulses to stimulate neurons and consequently modulates the physiological activity of the brain. TMS system is used in various clinical applications including: major depressive disorders, obsessive-compulsive disorder, smoking addiction and others various psychiatric, neurological, and addiction disorders. It operates in the Healthcare sector (SURGICAL AND MEDICAL INSTRUMENTS AND APPARATUS industry).

While Brainsway Ltd shows promising growth potential with a current price of $11.25 and a forward P/E ratio of 17.92, the RSI of 32.42 indicates it is currently oversold. The recent FDA approval for their Deep TMS technology and a strategic investment of $3 million in Radial Health are positive catalysts. However, the stock has seen a 15.48% decline over the past 20 days, suggesting caution. Given these factors, it may be wise to hold rather than buy at this moment.

暫無貼文

註冊或登入後參與討論

本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。

開始交易